Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives
02 Abril 2024 - 2:05PM
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the
appointment of Tim Benner as Senior Vice President of U.S. Sales
and Dr. Andrew Niekamp as Vice President of Medical Affairs. Mr.
Benner will be responsible for developing effective strategies
across the company's multi-product sales platform and leading a
high-performance commercial team to drive therapy penetration. Dr.
Niekamp will be instrumental in advancing Inari’s mission to
improve patient care through physician education and new device
development.
“We are thrilled to welcome Tim to Inari. His extensive
experience leading the commercial execution of disruptive
healthcare technologies will serve him well as he spearheads our
U.S. commercial efforts,” said Drew Hykes, CEO of Inari.
Mr. Benner joins Inari with more than 16 years of senior
leadership experience with high-growth and transformational medical
technology companies. Most recently, Tim spearheaded the global
launch and commercial execution of Saluda Medical’s disruptive
closed-loop neuromodulation platform. Before joining Saluda, Tim
was Global GM and SVP of Terumo’s Blood and Cell Technologies
business and led the global commercial business at Endologix. Prior
to his time at Terumo and Endologix, Tim was responsible for
commercial leadership of the U.S. Structural Heart business at
Abbott and oversaw the execution of hyper-growth therapies such as
MitraClip, Amulet, and Portico. Tim joined Abbott after
approximately 10 years at Edwards Lifesciences where he oversaw
several functions across Global Marketing, Commercial Operations,
Global Strategy, and Business Development. Tim began his career at
Honda where he worked in R&D and Advanced Development.
“Dr. Niekamp is a gifted clinician and a passionate and clear
communicator. We are honored to add his talents to our Medical
Affairs team,” said Dr. Thomas Tu, Chief Medical Officer of
Inari.
Prior to joining Inari, Dr. Niekamp was a Vascular
Interventional Radiologist with Radiology Associates of South
Florida and joined the group in July of 2020. He also practiced at
Baptist Hospital of Miami, South Miami Hospital and Doctors
Hospital. Dr. Niekamp received his undergraduate degree and medical
degree from The Ohio State University and completed his
post-graduate training at the University of Texas at Houston/M.D.
Anderson Cancer Center. He completed his fellowship in Vascular
Interventional Radiology at the Miami Cardiac and Vascular
Institute. Following fellowship, he joined the faculty at Miami
Cardiac and Vascular Institute and was a practicing attending until
March 2024. Dr. Niekamp has been an investigator in multiple
clinical research trials and is the author of numerous papers and
abstracts. During his time in practice, Dr. Niekamp had a
particular focus on treating patients suffering from venous
thromboembolism.
About Inari Medical, Inc.Patients first. No
small plans. Take care of each other. These are the guiding
principles that form the ethos of Inari Medical. We are committed
to improving lives in extraordinary ways by creating innovative
solutions for both unmet and underserved health needs. In addition
to our purpose-built solutions, we leverage our capabilities in
education, clinical research, and program development to improve
patient outcomes. We are passionate about our mission to establish
our treatments as the standard of care for venous disease,
including venous thromboembolism, chronic venous disease, and
beyond. We are just getting started. Learn more
at www.inarimedical.com and connect with us
on LinkedIn, X (Twitter), and Instagram.
Investor Contact:John Hsu, CFAVP, Investor
Relations949-658-3889IR@inarimedical.com
Inari Medical (NASDAQ:NARI)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Inari Medical (NASDAQ:NARI)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024